IL28B: Current and future use

Abstract

Host genetic variability in the vicinity of the IL28B gene is strongly associated with the outcome of pegylated interferon-α and ribavirin treatment for genotype 1 hepatitis C infection. In the setting of protease inhibitor triple therapy, this association is attenuated. However, IL28B genotype continues to be useful for guiding duration of therapy, as well as selecting the most cost-effective treatment regimen. Recent data suggests that IL28B genotype may remain relevant to future interferon-free regimens. This review explores the clinical role of IL28B genotyping in the context of current and evolving therapies.© 2012 Springer Science+Business Media, LLC.